Related Experiment Video
Updated: Nov 6, 2025
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
4.0K
Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues
1Department of Neurology, Division of Multiple Sclerosis and Neuroimmunology, Duke University Medical Center, Durham, North Carolina, U.S.A.; and.
Summary
Evoked potentials are reconsidered as outcome measures for multiple sclerosis clinical trials due to their ability to show pathophysiologic changes. Understanding their performance is crucial for regulatory approval of these biomarkers.
Area of Science:
- Neuroscience
- Clinical Trials
- Biomarkers
Background:
- Evoked potentials have historically aided multiple sclerosis diagnosis.
- Recent advancements highlight their potential for demonstrating pathophysiologic changes.
Purpose of the Study:
- To explore the regulatory considerations for using evoked potentials as surrogate end points in multiple sclerosis clinical trials.
- To emphasize the challenges associated with evoked potential studies in this context.
Main Methods:
- Review of regulatory guidelines for biomarkers and surrogate end points.
- Analysis of the utility and performance characteristics of evoked potentials in clinical trials.
Main Results:
- Evoked potentials show promise as outcome measures beyond diagnosis.
- Thorough understanding of performance characteristics is essential for biomarker utility.
Conclusions:
- Reconsideration of evoked potentials as outcome measures in multiple sclerosis trials is warranted.
- Regulatory hurdles and specific challenges in evoked potential studies need addressing for effective biomarker implementation.
More Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
66
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
66
01:13Bioequivalence studies: Biowaivers
52
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
52
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
218
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
218
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
47
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
47
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
38
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
38
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
55
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
55